{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:08:24Z","timestamp":1772136504685,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key R&D Program of Zhejiang","award":["No. 2022C03137"],"award-info":[{"award-number":["No. 2022C03137"]}]},{"name":"Zhejiang Medical Association Clinical Medical Research Special Fund Project","award":["No. 2022ZYC-D09"],"award-info":[{"award-number":["No. 2022ZYC-D09"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-89851-y","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T13:06:49Z","timestamp":1739884009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A nomogram for predicting T315I-free survival in chronic phase chronic myeloid leukemia patients: a multicenter retrospective study"],"prefix":"10.1038","volume":"15","author":[{"given":"Shi-wei","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-di","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di-jiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-qiong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-ying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-lan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-hong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-ping","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-yan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-feng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-ning","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-ming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-juan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-qing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gong-qiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-ming","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-li","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-jing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-yan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"89851_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl, S. et al. The biology of chronic myeloid leukemia. N. Engl. J. Med. 341, 164\u2013172. https:\/\/doi.org\/10.1056\/NEJM199907153410306 (1999).","journal-title":"N. Engl. J. Med."},{"key":"89851_CR2","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour, E. & Kantarjian, H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am. J. Hematol. 97, 1236\u20131256. https:\/\/doi.org\/10.1002\/ajh.26642 (2022).","journal-title":"Am. J. Hematol."},{"key":"89851_CR3","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","volume":"36","author":"TH Brummendorf","year":"2022","unstructured":"Brummendorf, T. H. et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: Final results from the BFORE trial. Leukemia 36, 1825\u20131833. https:\/\/doi.org\/10.1038\/s41375-022-01589-y (2022).","journal-title":"Leukemia"},{"key":"89851_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian, H. M. et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 35, 440\u2013453. https:\/\/doi.org\/10.1038\/s41375-020-01111-2 (2021).","journal-title":"Leukemia"},{"key":"89851_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","volume":"13","author":"J Senapati","year":"2023","unstructured":"Senapati, J. et al. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 13, 58. https:\/\/doi.org\/10.1038\/s41408-023-00823-9 (2023).","journal-title":"Blood Cancer J."},{"key":"89851_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/cbdd.13801","volume":"97","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation. Chem. Biol. Drug Des. 97, 649\u2013664. https:\/\/doi.org\/10.1111\/cbdd.13801 (2021).","journal-title":"Chem. Biol. Drug Des."},{"key":"89851_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","volume":"22","author":"NP Shah","year":"2024","unstructured":"Shah, N. P. et al. Chronic Myeloid Leukemia Version, 2.2024, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 22, 43\u201369. https:\/\/doi.org\/10.6004\/jnccn.2024.0007 (2024).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"89851_CR8","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.12688\/f1000research.74570.2","volume":"10","author":"M Al Hamad","year":"2021","unstructured":"Al Hamad, M. Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: A review. F1000Res 10, 1288. https:\/\/doi.org\/10.12688\/f1000research.74570.2 (2021).","journal-title":"F1000Res"},{"key":"89851_CR9","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/ajh.27037","volume":"98","author":"FG Haddad","year":"2023","unstructured":"Haddad, F. G. et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am. J. Hematol. 98, 1619\u20131626. https:\/\/doi.org\/10.1002\/ajh.27037 (2023).","journal-title":"Am. J. Hematol."},{"key":"89851_CR10","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","volume":"16","author":"VP Balachandran","year":"2015","unstructured":"Balachandran, V. P., Gonen, M., Smith, J. J. & DeMatteo, R. P. Nomograms in oncology: More than meets the eye. Lancet Oncol. 16, e173-180. https:\/\/doi.org\/10.1016\/S1470-2045(14)71116-7 (2015).","journal-title":"Lancet Oncol."},{"key":"89851_CR11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus, A. et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34, 966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2 (2020).","journal-title":"Leukemia"},{"key":"89851_CR12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3760\/cma.j.issn.0253-2727.2015.11.002","volume":"36","author":"Laboratory Diagnosis Group of Hematology Branch of Chinese Medical Association","year":"2015","unstructured":"Laboratory Diagnosis Group of Hematology Branch of Chinese Medical Association. Chinese expert consensus on the laboratory practice of BCR- ABL tyrosine kinase domain mutation detection. Zhonghua Xue Ye Xue Za Zhi 36, 899\u2013901. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2015.11.002 (2015).","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"89851_CR13","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"A Fabarius","year":"2011","unstructured":"Fabarius, A. et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV. Blood 118, 6760\u20136768. https:\/\/doi.org\/10.1182\/blood-2011-08-373902 (2011).","journal-title":"Blood"},{"key":"89851_CR14","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","volume":"34","author":"R Hehlmann","year":"2020","unstructured":"Hehlmann, R. et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia 34, 2074\u20132086. https:\/\/doi.org\/10.1038\/s41375-020-0826-9 (2020).","journal-title":"Leukemia"},{"key":"89851_CR15","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","volume":"247","author":"FE Harrell Jr","year":"1982","unstructured":"Harrell, F. E. Jr., Califf, R. M., Pryor, D. B., Lee, K. L. & Rosati, R. A. Evaluating the yield of medical tests. JAMA 247, 2543\u20132546 (1982).","journal-title":"JAMA"},{"key":"89851_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","volume":"143","author":"JA Hanley","year":"1982","unstructured":"Hanley, J. A. & McNeil, B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29\u201336. https:\/\/doi.org\/10.1148\/radiology.143.1.7063747 (1982).","journal-title":"Radiology"},{"key":"89851_CR17","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1001\/jama.2017.12126","volume":"318","author":"AC Alba","year":"2017","unstructured":"Alba, A. C. et al. Discrimination and calibration of clinical prediction models: Users\u2019 guides to the medical literature. JAMA 318, 1377\u20131384. https:\/\/doi.org\/10.1001\/jama.2017.12126 (2017).","journal-title":"JAMA"},{"key":"89851_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41512-019-0064-7","volume":"3","author":"AJ Vickers","year":"2019","unstructured":"Vickers, A. J., van Calster, B. & Steyerberg, E. W. A simple, step-by-step guide to interpreting decision curve analysis. Diagn. Progn. Res. 3, 18. https:\/\/doi.org\/10.1186\/s41512-019-0064-7 (2019).","journal-title":"Diagn. Progn. Res."},{"key":"89851_CR19","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","volume":"114","author":"FE Nicolini","year":"2009","unstructured":"Nicolini, F. E. et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood 114, 5271\u20135278. https:\/\/doi.org\/10.1182\/blood-2009-04-219410 (2009).","journal-title":"Blood"},{"key":"89851_CR20","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1002\/cncr.30558","volume":"123","author":"FE Nicolini","year":"2017","unstructured":"Nicolini, F. E. et al. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer 123, 2875\u20132880. https:\/\/doi.org\/10.1002\/cncr.30558 (2017).","journal-title":"Cancer"},{"key":"89851_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood.2019002969","volume":"135","author":"S Soverini","year":"2020","unstructured":"Soverini, S. et al. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: The NEXT-in-CML study. Blood 135, 534\u2013541. https:\/\/doi.org\/10.1182\/blood.2019002969 (2020).","journal-title":"Blood"},{"key":"89851_CR22","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1038\/s41375-022-01616-y","volume":"36","author":"XS Zhang","year":"2022","unstructured":"Zhang, X. S. et al. Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy. Leukemia 36, 2042\u20132049. https:\/\/doi.org\/10.1038\/s41375-022-01616-y (2022).","journal-title":"Leukemia"},{"key":"89851_CR23","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1182\/blood.2022017295","volume":"141","author":"V Krishnan","year":"2023","unstructured":"Krishnan, V. et al. A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia. Blood 141, 2738\u20132755. https:\/\/doi.org\/10.1182\/blood.2022017295 (2023).","journal-title":"Blood"},{"key":"89851_CR24","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41375-022-01527-y","volume":"36","author":"XS Zhang","year":"2022","unstructured":"Zhang, X. S., Gale, R. P., Zhang, M. J., Huang, X. J. & Jiang, Q. A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy. Leukemia 36, 1336\u20131342. https:\/\/doi.org\/10.1038\/s41375-022-01527-y (2022).","journal-title":"Leukemia"},{"key":"89851_CR25","doi-asserted-by":"publisher","first-page":"1212392","DOI":"10.3389\/fphar.2023.1212392","volume":"14","author":"H Jacobi","year":"2023","unstructured":"Jacobi, H. et al. Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients. Front. Pharmacol. 14, 1212392. https:\/\/doi.org\/10.3389\/fphar.2023.1212392 (2023).","journal-title":"Front. Pharmacol."},{"key":"89851_CR26","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/14737159.2017.1383156","volume":"17","author":"M Molica","year":"2017","unstructured":"Molica, M., Massaro, F. & Breccia, M. Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: An update. Expert Rev. Mol. Diagn. 17, 1001\u20131008. https:\/\/doi.org\/10.1080\/14737159.2017.1383156 (2017).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"89851_CR27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/leu.2016.231","volume":"31","author":"Z Chen","year":"2017","unstructured":"Chen, Z. et al. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia 31, 585\u2013592. https:\/\/doi.org\/10.1038\/leu.2016.231 (2017).","journal-title":"Leukemia"},{"key":"89851_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11899-012-0119-0","volume":"7","author":"N Muvarak","year":"2012","unstructured":"Muvarak, N., Nagaria, P. & Rassool, F. V. Genomic instability in chronic myeloid leukemia: Targets for therapy?. Curr. Hematol. Malig. Rep. 7, 94\u2013102. https:\/\/doi.org\/10.1007\/s11899-012-0119-0 (2012).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"89851_CR29","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3390\/ijms21041177","volume":"21","author":"HD Popp","year":"2020","unstructured":"Popp, H. D. et al. DNA damage and DNA damage response in chronic myeloid leukemia. Int. J. Mol. Sci. 21, 1177. https:\/\/doi.org\/10.3390\/ijms21041177 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"89851_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02278-8","author":"JE Cortes","year":"2024","unstructured":"Cortes, J. E. et al. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after >\/=1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia https:\/\/doi.org\/10.1038\/s41375-024-02278-8 (2024).","journal-title":"Leukemia"},{"key":"89851_CR31","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian, H. M. et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119, 1123\u20131129. https:\/\/doi.org\/10.1182\/blood-2011-08-376087 (2012).","journal-title":"Blood"},{"key":"89851_CR32","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","volume":"121","author":"P Neelakantan","year":"2013","unstructured":"Neelakantan, P. et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: Implications for early intervention strategies. Blood 121, 2739\u20132742. https:\/\/doi.org\/10.1182\/blood-2012-11-466037 (2013).","journal-title":"Blood"},{"key":"89851_CR33","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","volume":"118","author":"E Jabbour","year":"2011","unstructured":"Jabbour, E. et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 118, 4541\u20134546. https:\/\/doi.org\/10.1182\/blood-2011-04-348110 (2011) (quiz 4759).","journal-title":"Blood"},{"key":"89851_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-019-0815-5","volume":"12","author":"S Soverini","year":"2019","unstructured":"Soverini, S. et al. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: A position paper. J. Hematol. Oncol. 12, 131. https:\/\/doi.org\/10.1186\/s13045-019-0815-5 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"89851_CR35","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3324\/haematol.2016.145888","volume":"101","author":"C Baer","year":"2016","unstructured":"Baer, C. et al. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia. Haematologica 101, 830\u2013838. https:\/\/doi.org\/10.3324\/haematol.2016.145888 (2016).","journal-title":"Haematologica"},{"key":"89851_CR36","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/s41375-022-01648-4","volume":"36","author":"L Schonfeld","year":"2022","unstructured":"Schonfeld, L. et al. ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia 36, 2242\u20132249. https:\/\/doi.org\/10.1038\/s41375-022-01648-4 (2022).","journal-title":"Leukemia"},{"key":"89851_CR37","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1038\/s41467-021-23097-w","volume":"12","author":"Y Ochi","year":"2021","unstructured":"Ochi, Y. et al. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nat. Commun. 12, 2833. https:\/\/doi.org\/10.1038\/s41467-021-23097-w (2021).","journal-title":"Nat. Commun."},{"key":"89851_CR38","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.bioactmat.2022.08.006","volume":"21","author":"Q Qiu","year":"2023","unstructured":"Qiu, Q. et al. HDAC I\/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells. Bioact. Mater. 21, 483\u2013498. https:\/\/doi.org\/10.1016\/j.bioactmat.2022.08.006 (2023).","journal-title":"Bioact. Mater."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89851-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89851-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89851-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T13:06:56Z","timestamp":1739884016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89851-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89851"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89851-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4943970\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the Ethics Committee of the First Affiliated Hospital, School of Medicine, Zhejiang University Institutional Review Board, with a waiver for informed consent (2022, No469). All methods were carried out in accordance with relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"5965"}}